Ustekinumab for psoriatic arthritis

The Lancet

Volumn 373, Issue 9664, 2009, Pages 605-606

  Cuchacovich, Raquel S ^a   Espinoza, Luis R ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; USTEKINUMAB;

ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; UNSPECIFIED SIDE EFFECT;

EID: 60249091170     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60141-0     Document Type: Note

References (12)

1. Lowes M.A., Bowcock A.M., and Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 445 (2007) 866-873
2. Candia L., Marquez J., Hernandez C., Zea A.H., and Espinoza L.R. Toll-like receptor-2 expression is up-regulated in antigen presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity. J Rheumatol 34 (2007) 374-379
3. Steiman L. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat Med 13 (2007) 139-145
4. Fitch E., Harper E., Skorcheva I., Kurtz S.E., and Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and TH17 cytokines. Curr Rheumatol Rep 9 (2007) 461-467
5. Piskin G., Sylva-Steenland R.M.R., Bos J.D., and Teunissen M.B.M. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 176 (2006) 1908-1915
6. Genovese M.C., Mease P.J., Thomson G.T.D., et al., on behalf of the MO2-570 study group. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 34 (2007) 1040-1050
7. Papp K.A., Langley R.G., Lebwohl M., et al., for the PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371 (2008) 1675-1684
8. Gottlieb A., Menter A., Mendelsohn A., et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet (2009) 10.1016/S0140-6736(09)60140-9 published online Feb 12.
9. Helliwell P.S., Taylor W.J., and on behalf of the Caspar Study Group. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs-comparison of drugs and adverse reactions. J Rheumatol 35 (2008) 472-476
10. Taylor W., Gladman D., Helliwell P., Marchesoni A., Mease P., Mielants H., and on behalf of the Caspar Study Group. Classification criteria for psoriatic arthritis development of new criteria from a large international study. Arthritis Rheum 54 (2006) 2665-2673
11. Cuchacovich R., Espinoza C.G., Virk Z., and Espinoza L.R. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha?. J Clin Rheumatol 14 (2008) 353-356
12. Saketkoo L.A., Cuchacovich R., and Espinoza L.R. Methotrexate therapy for psoriatic arthritis: reappraisal of an old remedy. J Rheumatol 35 (2008) 369-371